News from durect corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 18, 2022, 13:53 ET DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. Norman Sussman, Chief Medical Officer, and Dr....

May 04, 2022, 16:05 ET DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2022 and provided a corporate update....

Apr 27, 2022, 16:15 ET DURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4

DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after the...

Mar 23, 2022, 16:15 ET DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, will be participating in a panel discussion at the...

Mar 09, 2022, 16:30 ET DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. WeiQi Lin, Executive Vice President of R&D and Dr....

Mar 07, 2022, 16:05 ET DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2021 and provided a corporate...

Mar 01, 2022, 08:30 ET DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis

DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first patient in the European Union as part of its AHFIRM randomized, double-blind,...

Feb 28, 2022, 16:30 ET DURECT Corporation to Announce Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 7

DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2021 financial results and host a conference...

Jan 06, 2022, 16:05 ET DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr....

Dec 22, 2021, 07:30 ET DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)

DURECT Corporation (Nasdaq: DRRX) today announced a licensing agreement granting Innocoll Biotherapeutics plc, a specialty pharmaceutical company and ...

Dec 14, 2021, 09:00 ET DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia

DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its board of directors with the appointment of Peter García, a biopharmaceutical...

Nov 29, 2021, 09:00 ET DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit

DURECT Corporation (Nasdaq: DRRX) announced it will participate in a workshop today at the 5th Annual NASH Summit being held virtually from today...

Nov 12, 2021, 09:00 ET Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S.

DURECT Corporation (Nasdaq: DRRX) today announced the presentation of data at the American Association for The Study of Liver Diseases (AASLD) The...

Nov 10, 2021, 09:00 ET DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis

DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first ex-U.S. patient in Australia as part of its AHFIRM randomized, double-blind,...

Nov 08, 2021, 09:00 ET DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting® 2021

DURECT Corporation (Nasdaq: DRRX) today announced that Suthat Liangpunsakul, M.D. will present a poster at the American Association for The Study of...

Nov 02, 2021, 16:05 ET DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2021 and provided a corporate update. "I ...

Oct 26, 2021, 09:00 ET DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide Business Update on November 2

DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2021 financial results and host a conference call after the...

Oct 07, 2021, 09:00 ET DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Conference

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr....

Sep 23, 2021, 09:00 ET DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr....

Sep 15, 2021, 09:00 ET DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr....

Sep 07, 2021, 09:00 ET DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global Investment Conference

DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman...

Jul 29, 2021, 16:05 ET DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2021 and provided a corporate update. Q2 2021 ...

Jul 22, 2021, 08:30 ET DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29

DURECT Corporation (Nasdaq: DRRX) today announced that it will report its second quarter 2021 financial results and host a conference call after the...

Jul 14, 2021, 16:30 ET DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit

DURECT Corporation (Nasdaq: DRRX) today announced it will present at the Epigenetic Therapeutic Targets Summit, being held virtually July 13-15, 2021....

Jun 23, 2021, 09:00 ET DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL)

DURECT Corporation (Nasdaq: DRRX) today announced the presentation of additional clinical data from a DUR-928 Phase 1b trial in non-alcoholic...